Market Cap 93.33M
Revenue (ttm) 0.00
Net Income (ttm) -138.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 494,500
Avg Vol 1,193,110
Day's Range N/A - N/A
Shares Out 70.70M
Stochastic %K 61%
Beta -0.16
Analysts Strong Sell
Price Target $7.00

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle con...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 980 9099
Address:
1599 Industrial Road, San Carlos, United States
Mr_GA
Mr_GA Feb. 24 at 1:39 AM
0 · Reply
Mr_GA
Mr_GA Feb. 24 at 1:36 AM
$BMEA https://www.biospace.com/business/redefining-obesity-treatment-beyond-glp-1-limits?hsCtaAttrib=181036624458
0 · Reply
Felo254
Felo254 Feb. 23 at 11:11 PM
$BMEA Been slowly building a position here but don’t know the implications of this STEM cell therapy is for us here…
1 · Reply
Arxidia
Arxidia Feb. 23 at 10:20 PM
$BMEA Keep an eye/ear out for the upcoming conference on Thursady - listen for the tone. If they sound confident about "completing all cohorts" which woupd mean including the tolerance-tricky 400mg cohort, we are looking *really* good!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 9:53 PM
$BMEA RSI: 65.00, MACD: -0.0004 Vol: 0.08, MA20: 1.24, MA50: 1.32 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Mr_GA
Mr_GA Feb. 23 at 8:55 PM
0 · Reply
Onethousand1
Onethousand1 Feb. 23 at 8:45 PM
$BMEA is the $NVO data update not good news for bmea? I guess we'll have to wait till Q2 for data read out.
1 · Reply
Arxidia
Arxidia Feb. 23 at 6:53 PM
$BMEA When a giant like Novo loses a major battle - like they did today with their obesity molecule - they often go on a shopping spree. If the BMF650 proof of concept trial (results expected Apr - Jun) proves that the molecule is faster or more efficient than both Lilly and Novo (like it did in the primate trial!), Biomea becomes the number 1 acquisition target for a company that needs to "reclaim the throne." Watch this space … we are likely currently in Cohort 3 (300mg) or the start of the final Cohort 4 (400mg) right now!
1 · Reply
Newby_Trader_101
Newby_Trader_101 Feb. 23 at 12:19 AM
$BMEA Oh, I also opened a small position here too; 60k shares. Looks like this one might have to marinate for a little bit before cooking unless a BIG surprise happens. GL Bulls!
2 · Reply
LouKojak
LouKojak Feb. 22 at 10:15 PM
0 · Reply
Latest News on BMEA
Biomea Fusion to Participate at Upcoming Investor Conferences

Feb 19, 2026, 7:00 AM EST - 4 days ago

Biomea Fusion to Participate at Upcoming Investor Conferences


Biomea Fusion, Inc. - Special Call

Oct 7, 2025, 12:05 PM EDT - 4 months ago

Biomea Fusion, Inc. - Special Call


Biomea Fusion Announces Proposed Public Offering of Securities

Oct 6, 2025, 4:18 PM EDT - 5 months ago

Biomea Fusion Announces Proposed Public Offering of Securities


Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Jun 17, 2025, 7:28 PM EDT - 8 months ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR


Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 11 months ago

Biomea Fusion Announces Leadership Transition


Mr_GA
Mr_GA Feb. 24 at 1:39 AM
0 · Reply
Mr_GA
Mr_GA Feb. 24 at 1:36 AM
$BMEA https://www.biospace.com/business/redefining-obesity-treatment-beyond-glp-1-limits?hsCtaAttrib=181036624458
0 · Reply
Felo254
Felo254 Feb. 23 at 11:11 PM
$BMEA Been slowly building a position here but don’t know the implications of this STEM cell therapy is for us here…
1 · Reply
Arxidia
Arxidia Feb. 23 at 10:20 PM
$BMEA Keep an eye/ear out for the upcoming conference on Thursady - listen for the tone. If they sound confident about "completing all cohorts" which woupd mean including the tolerance-tricky 400mg cohort, we are looking *really* good!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 9:53 PM
$BMEA RSI: 65.00, MACD: -0.0004 Vol: 0.08, MA20: 1.24, MA50: 1.32 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Mr_GA
Mr_GA Feb. 23 at 8:55 PM
0 · Reply
Onethousand1
Onethousand1 Feb. 23 at 8:45 PM
$BMEA is the $NVO data update not good news for bmea? I guess we'll have to wait till Q2 for data read out.
1 · Reply
Arxidia
Arxidia Feb. 23 at 6:53 PM
$BMEA When a giant like Novo loses a major battle - like they did today with their obesity molecule - they often go on a shopping spree. If the BMF650 proof of concept trial (results expected Apr - Jun) proves that the molecule is faster or more efficient than both Lilly and Novo (like it did in the primate trial!), Biomea becomes the number 1 acquisition target for a company that needs to "reclaim the throne." Watch this space … we are likely currently in Cohort 3 (300mg) or the start of the final Cohort 4 (400mg) right now!
1 · Reply
Newby_Trader_101
Newby_Trader_101 Feb. 23 at 12:19 AM
$BMEA Oh, I also opened a small position here too; 60k shares. Looks like this one might have to marinate for a little bit before cooking unless a BIG surprise happens. GL Bulls!
2 · Reply
LouKojak
LouKojak Feb. 22 at 10:15 PM
0 · Reply
Trifecta1231
Trifecta1231 Feb. 22 at 3:38 AM
$BMEA could end up in a little bit of a short squeeze by the summer if early data comes out... short % creeping up, dance carefully bears
0 · Reply
Newby_Trader_101
Newby_Trader_101 Feb. 21 at 4:49 PM
$MLTX Thanks to @creisi, I was led to this stock. I read his posts from $BMEA board. I was in that board because of some odd coincidences that leads back to $OPEN stock, which I have most of my funds in. You should check that out. Anyways, I am NOT a biotech guy. You don't have to agree with everything creisi says, but you need people like him. He's the only reason I'm here. He attracts new investors and keeps existing investors motivated. Everyone has brains to do their own DD. After trading this for the last two weeks, I took a long position yesterday on that dip between 17.40 to 17.60. My novice opinion says this is looking very bullish. GL to all the bulls...
2 · Reply
Creisi
Creisi Feb. 20 at 9:33 PM
$BMEA UTTER AND COMPLETE BULLSHIT! The poster claiming BMEA's Covalent trial did not meet primary end points is 100% FALSE! BMEA Covalent trial met all primary end points. PERIOD. Saying otherwise is simply false and if done intentionally, a fraudulent attempt to deceive investors. Please refrain from posting fraudulent messages again.
2 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Feb. 20 at 4:57 PM
$BMEA lots of chatter and banter here recently...thats very good. It mean ones this baby pops...oO it will be a feast 💲💲💲 Shorts will need to cover and fanboys will pour coal into the engine That train will be fast and parabolic. Better to be on board before we leave the station 🚉
1 · Reply
MuffinStuffur
MuffinStuffur Feb. 20 at 4:24 PM
0 · Reply
BobBijawklah
BobBijawklah Feb. 20 at 6:22 AM
$BMEA look a lot of people cannot digest the disparity between stock price today vs stock price if icovamenib makes it to market. Start with the first trial did not meet its endpoint and they selected sidd data subset as being the best possible avenue to market. As a result of the pivot the company has to re do the phase 2 trial. You have to consider it is plausible that the data in the larger SIDD group will show less efficacy . We don't know for sure but the value of company if they gain approval will be 5x-10x current price. So it's confusing. Gang hold your shares
2 · Reply
Reneejordan001
Reneejordan001 Feb. 19 at 10:20 PM
$BMEA Just mute or block the noise. I just did 👍👌
0 · Reply
Newcar
Newcar Feb. 19 at 2:14 PM
$BMEA If the therapies were truly promising, the company's value wouldn't be so low, considering the huge interest in treating diabetes and obesity. There's something wrong that we don't know. The market doesn't trust them.
3 · Reply
BigBeardTrader
BigBeardTrader Feb. 19 at 2:01 PM
$BMEA https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-participate-upcoming-investor-conferences-0
2 · Reply
BobBijawklah
BobBijawklah Feb. 19 at 1:20 PM
$BMEA if bmf650 shows superior safety and marketable efficacy easily doubles stock price. Regarding icovamenib that drug has another double from there. So 5 dollars is a safe target in next 12 months
0 · Reply
Apes_Strong
Apes_Strong Feb. 19 at 12:48 PM
$BMEA I fail to understand how/why unexercised warrants out of the money are a 13G ownership disclosure obligation
1 · Reply
asa123
asa123 Feb. 19 at 4:06 AM
$BMEA @Apes_Strong These aren’t common shares — they’re warrants, same as Blue Owl a few days ago. Check item 4 - Ownership amount beneficially owned in the CVI/Heights filing. If you add Blue Owl’s 4.4M warrants to CVI/Heights 7.8M, you’re basically at 13M warrants total. That happens to match the size of the October warrant issuance almost exactly. If these are indeed October warrants (as opposed to June warrants), then the entire October warrant pool is now accounted for in just two institutional hands. Since these warrants were probably acquired for something like $0.50 on the secondary market, this isn’t a trade to clip pennies. The breakeven math alone already pushes you above $3, and that’s before factoring in time value, risk, and opportunity cost.
1 · Reply